Literature DB >> 11463009

Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation.

H Meijers-Heijboer1, B van Geel, W L van Putten, S C Henzen-Logmans, C Seynaeve, M B Menke-Pluymers, C C Bartels, L C Verhoog, A M van den Ouweland, M F Niermeijer, C T Brekelmans, J G Klijn.   

Abstract

BACKGROUND: Women with a BRCA1 or BRCA2 mutation have a high risk of breast cancer and may choose to undergo prophylactic bilateral total mastectomy. We investigated the efficacy of this procedure in such women.
METHODS: We conducted a prospective study of 139 women with a pathogenic BRCA1 or BRCA2 mutation who were enrolled in a breast-cancer surveillance program at the Rotterdam Family Cancer Clinic. At the time of enrollment, none of the women had a history of breast cancer. Seventy-six of these women eventually underwent prophylactic mastectomy, and the other 63 remained under regular surveillance. The effect of mastectomy on the incidence of breast cancer was analyzed by the Cox proportional-hazards method in which mastectomy was modeled as a time-dependent covariate.
RESULTS: No cases of breast cancer were observed after prophylactic mastectomy after a mean (+/-SE) follow-up of 2.9+/-1.4 years, whereas eight breast cancers developed in women under regular surveillance after a mean follow-up of 3.0+/-1.5 years (P=0.003; hazard ratio, 0; 95 percent confidence interval, 0 to 0.36). The actuarial mean five-year incidence of breast cancer among all women in the surveillance group was 17+/-7 percent. On the basis of an exponential model, the yearly incidence of breast cancer in this group was 2.5 percent. The observed number of breast cancers in the surveillance group was consistent with the expected number (ratio of observed to expected cases, 1.2; 95 percent confidence interval, 0.4 to 3.7; P=0.80).
CONCLUSIONS: In women with a BRCA1 or BRCA2 mutation, prophylactic bilateral total mastectomy reduces the incidence of breast cancer at three years of follow-up.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11463009     DOI: 10.1056/NEJM200107193450301

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  169 in total

Review 1.  Breast cancer.

Authors:  Monica Morrow; William Gradishar
Journal:  BMJ       Date:  2002-02-16

Review 2.  Hereditary breast and ovarian cancer: new genes, new treatments, new concepts.

Authors:  Alfons Meindl; Nina Ditsch; Karin Kast; Kerstin Rhiem; Rita K Schmutzler
Journal:  Dtsch Arztebl Int       Date:  2011-05-13       Impact factor: 5.594

Review 3.  Modern trends into the epidemiology and screening of ovarian cancer. Genetic substrate of the sporadic form.

Authors:  Maria Koutsaki; Apostolos Zaravinos; Demetrios A Spandidos
Journal:  Pathol Oncol Res       Date:  2011-12-09       Impact factor: 3.201

Review 4.  Genetics for the general internist.

Authors:  Christina M Laukaitis
Journal:  Am J Med       Date:  2011-11-11       Impact factor: 4.965

5.  Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial.

Authors:  Pascal Pujol; Christine Lasset; Pascaline Berthet; Catherine Dugast; Suzette Delaloge; Jean-Pierre Fricker; Isabelle Tennevet; Nathalie Chabbert-Buffet; Pascale This; Karen Baudry; Jerome Lemonnier; Lise Roca; Sylvie Mijonnet; Paul Gesta; Jean Chiesa; Helene Dreyfus; Philippe Vennin; Capucine Delnatte; Yves Jean Bignon; Alain Lortholary; Fabienne Prieur; Laurence Gladieff; Anne Lesur; Krishna B Clough; Catherine Nogues; Anne-Laure Martin
Journal:  Fam Cancer       Date:  2012-03       Impact factor: 2.375

Review 6.  Genetic risk assessments in individuals at high risk for inherited breast cancer in the breast oncology care setting.

Authors:  Tuya Pal; Susan T Vadaparampil
Journal:  Cancer Control       Date:  2012-10       Impact factor: 3.302

7.  High prevalence of preinvasive lesions adjacent to BRCA1/2-associated breast cancers.

Authors:  Banu Arun; Kristen J Vogel; Adriana Lopez; Mike Hernandez; Deann Atchley; Kristine R Broglio; Christopher I Amos; Funda Meric-Bernstam; Henry Kuerer; Gabriel N Hortobagyi; Constance T Albarracin
Journal:  Cancer Prev Res (Phila)       Date:  2009-01-27

Review 8.  Management updates for women with a BRCA1 or BRCA2 mutation.

Authors:  Rachel Nusbaum; Claudine Isaacs
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

Review 9.  Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions.

Authors:  David L Kleinberg; Teresa L Wood; Priscilla A Furth; Adrian V Lee
Journal:  Endocr Rev       Date:  2008-12-15       Impact factor: 19.871

10.  American Society of Clinical Oncology policy statement: the role of the oncologist in cancer prevention and risk assessment.

Authors:  Robin T Zon; Elizabeth Goss; Victor G Vogel; Rowan T Chlebowski; Ismail Jatoi; Mark E Robson; Dana S Wollins; Judy E Garber; Powel Brown; Barnett S Kramer
Journal:  J Clin Oncol       Date:  2008-12-15       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.